Publicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (50)

2024

  1. Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers

    British Journal of Surgery, Vol. 111, Núm. 3

  2. Cost-effectiveness of robotic vs laparoscopic distal pancreatectomy. Results from the national prospective trial ROBOCOSTES

    Surgical Endoscopy

  3. Impact of primary aldosteronism on kidney function: Results from the SPAIN-ALDO registry

    Journal of Hypertension, Vol. 42, Núm. 10, pp. 1805-1812

2023

  1. Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics

    Clinical Cancer Research, Vol. 29, Núm. 12, pp. 2250-2265

  2. Patient Reported Outcomes following Cancer of the Rectum (PROCaRe): protocol of a prospective multicentre international study

    Techniques in Coloproctology, Vol. 27, Núm. 12, pp. 1345-1350

  3. Telomere Length as a New Risk Marker of Early-Onset Colorectal Cancer

    International Journal of Molecular Sciences, Vol. 24, Núm. 4

2022

  1. Erratum to ‘Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors’: [ESMO Open Volume 7, Issue 2, April 2022, 100447] (ESMO Open (2022) 7(2), (S2059702922000631), (10.1016/j.esmoop.2022.100447))

    ESMO Open

  2. Quality of Colonoscopy Is Associated With Adenoma Detection and Postcolonoscopy Colorectal Cancer Prevention in Lynch Syndrome

    Clinical Gastroenterology and Hepatology, Vol. 20, Núm. 3, pp. 611-621.e9

  3. Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors

    ESMO Open, Vol. 7, Núm. 2

  4. Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery

    BJS Open, Vol. 6, Núm. 1

2021

  1. A CT-based radiomics signature is associated with response to immune checkpoint inhibitors in advanced solid tumors

    Radiology, Vol. 299, Núm. 1, pp. 109-119

  2. Clarification of Definitions of Hyperprogressive Disease during Immunotherapy

    JAMA Oncology

  3. Cohort profile: The Spanish Early-onset Colorectal Cancer (SECOC) cohort: A multicentre cohort study on the molecular basis of colorectal cancer among young individuals in Spain

    BMJ Open, Vol. 11, Núm. 12

  4. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study

    The Lancet Respiratory Medicine, Vol. 9, Núm. 6, pp. 613-621

  5. Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)

    Journal of Clinical Oncology, Vol. 39, Núm. 20, pp. 2304-2312

  6. Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials

    European Journal of Cancer, Vol. 155, pp. 168-178

  7. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

    The Lancet Diabetes and Endocrinology, Vol. 9, Núm. 8, pp. 491-501

  8. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

    The Lancet Oncology, Vol. 22, Núm. 6, pp. 779-789

2020

  1. Atypical patterns of response and progression in the era of immunotherapy combinations

    Future Oncology, Vol. 16, Núm. 23, pp. 1707-1713

  2. Capturing hyperprogressive disease with immune-checkpoint inhibitors using RECIST 1.1 criteria

    Clinical Cancer Research, Vol. 26, Núm. 8, pp. 1846-1855